🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

294,83 USD

Máx. histórico

294,89

5 días

Caída desde máximo

-0,02%

Rango 52 semanas

190,75 – 298,74

Variación hoy

+3,09%

Cierre anterior

286,00

Rango de hoy

283,32 – 295,40

Volumen hoy

8.408.135

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,30%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
51,19 (puede no estar actualizado)
Dividend yield
2,42% (puede no estar actualizado)
Precio objetivo analistas
306,42 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 11 horas
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,35%
Fecha de pago Importe por participación
15/10/2026 1,7300 USD
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/03/2019 81,34 81,75 80,28 80,65 -0,85% 1,81% 5.550.100
15/03/2019 80,06 81,46 79,11 81,34 +1,74% 2,94% 12.751.100
14/03/2019 79,00 80,40 78,41 79,95 +1,29% 2,52% 6.161.800
13/03/2019 78,92 79,30 78,15 78,93 +0,24% 1,46% 5.984.500
12/03/2019 78,48 79,14 78,05 78,74 +0,85% 1,39% 6.128.800
11/03/2019 77,57 78,31 77,27 78,08 +0,64% 1,34% 8.078.100
08/03/2019 77,67 78,04 77,09 77,58 -0,84% 1,22% 6.189.100
07/03/2019 77,77 79,12 77,44 78,24 +0,19% 2,16% 6.642.500
06/03/2019 79,13 79,13 77,56 78,09 -1,04% 1,98% 5.293.200
05/03/2019 79,38 79,90 78,72 78,91 -0,69% 1,49% 5.933.100
04/03/2019 80,40 80,73 79,11 79,46 -0,80% 2,01% 5.872.500
01/03/2019 79,77 80,85 79,28 80,10 +1,09% 1,97% 8.567.900
28/02/2019 79,46 79,71 78,75 79,24 -0,21% 1,21% 6.310.800
27/02/2019 80,14 80,14 78,80 79,41 -1,37% 1,67% 4.175.500
26/02/2019 80,20 80,86 80,02 80,51 +0,27% 1,05% 4.283.100
25/02/2019 80,46 80,62 79,88 80,29 +0,34% 0,92% 5.511.800
22/02/2019 79,16 80,19 78,24 80,02 +1,61% 2,46% 5.022.700
21/02/2019 79,74 79,91 78,10 78,75 -1,55% 2,27% 6.360.800
20/02/2019 80,53 80,60 79,14 79,99 -0,66% 1,81% 5.564.100
19/02/2019 80,50 81,52 80,23 80,52 -0,41% 1,60% 5.674.700
15/02/2019 81,13 81,70 80,16 80,85 +0,41% 1,90% 6.295.400
14/02/2019 80,45 80,68 79,72 80,52 -0,33% 1,19% 3.436.300
13/02/2019 80,34 81,32 80,29 80,79 +1,08% 1,28% 4.237.200
12/02/2019 79,99 80,12 78,57 79,93 +0,20% 1,94% 6.620.100
11/02/2019 79,89 80,18 79,17 79,77 +0,13% 1,26% 4.803.500
08/02/2019 79,03 79,86 78,89 79,67 +0,63% 1,23% 4.598.900
07/02/2019 78,35 79,22 77,81 79,17 +0,11% 1,80% 5.877.500
06/02/2019 79,60 79,89 78,79 79,08 -0,77% 1,38% 4.907.200
05/02/2019 78,56 80,06 78,22 79,69 +1,48% 2,34% 7.965.500
04/02/2019 80,30 80,36 77,52 78,53 -2,45% 3,54% 10.205.600